Literature DB >> 6345395

Cytotoxic effect of an alpha-hemolytic Escherichia coli strain on human blood monocytes and granulocytes in vitro.

O V Gadeberg, I Orskov, J M Rhodes.   

Abstract

The alpha-hemolytic Escherichia coli strain C134-73 Hly+ was primarily cytocidal to human blood monocytes and granulocytes in vitro in the presence of fresh autologous plasma. Monocytes and granulocytes underwent marked morphological changes during incubation with the bacteria, and the percentages of intact phagocytes decreased progressively with the time of incubation. The cytotoxic effect increased with the number of bacteria per phagocyte and was produced by log-phase microorganisms only. Neither free hemolysin nor free cytotoxic activity to leukocytes could be detected in the incubation medium if the bacteria were removed from the test system. Bacteria-free culture supernatants containing alpha-hemolysin were cytotoxic to monocytes, granulocytes, and lymphocytes, monocytes and granulocytes being the most sensitive. However, this effect was abolished by fresh autologous plasma. Two nonhemolytic strains, a mutant derivative of C134-73 Hly+ and strain X43, were not cytotoxic. These observations suggest that alpha-hemolysin associated with the bacterial cells may enhance the virulence of E. coli by injuring phagocytes, whereas free alpha-hemolysin may be of minor importance because its cytotoxic effect is neutralized by host plasma.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6345395      PMCID: PMC264786          DOI: 10.1128/iai.41.1.358-364.1983

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  15 in total

1.  Properties of strains of Escherichia coli isolated from a variety of sources.

Authors:  E M Cooke; S P Ewins
Journal:  J Med Microbiol       Date:  1975-02       Impact factor: 2.472

2.  Isolation of lymphocytes, granulocytes and macrophages.

Authors:  A Bøyum
Journal:  Scand J Immunol       Date:  1976-06       Impact factor: 3.487

3.  Identification of human mononuclear leucocyte populations by esterase staining.

Authors:  D A Horwitz; A C Allison; P Ward; N Kight
Journal:  Clin Exp Immunol       Date:  1977-11       Impact factor: 4.330

4.  Antitoxic immunity against the so-called lung toxin produced by Escherichia coli.

Authors:  L Emödy; I Kétyi; B Kuch; S Pácsa
Journal:  Acta Microbiol Acad Sci Hung       Date:  1979

5.  alpha-Haemolysin: an additive virulence factor in Escherichia coli.

Authors:  L Emödy; T Pál; N V Safonova; B Kuch; N K Golutva
Journal:  Acta Microbiol Acad Sci Hung       Date:  1980

6.  Evidence of cytocidal effects of Pasteurella haemolytica on bovine peripheral blood mononuclear leukocytes.

Authors:  K L Kaehler; R J Markam; C C Muscoplat; D W Johnson
Journal:  Am J Vet Res       Date:  1980-10       Impact factor: 1.156

7.  Cytotoxicity of filtrates of haemolytic Escherichia coli.

Authors:  U C Chaturvedi; A Mathur; A M Khan; R M Mehrotra
Journal:  J Med Microbiol       Date:  1969-08       Impact factor: 2.472

8.  Observations on the pathogenic properties of the K88, Hly and Ent plasmids of Escherichia coli with particular reference to porcine diarrhoea.

Authors:  H W Smith; M A Linggood
Journal:  J Med Microbiol       Date:  1971-11       Impact factor: 2.472

9.  Association of hemolysin production, hemagglutination of human erythrocytes, and virulence for chicken embryos of extraintestinal Escherichia coli isolates.

Authors:  B H Minshew; J Jorgensen; G W Counts; S Falkow
Journal:  Infect Immun       Date:  1978-04       Impact factor: 3.441

10.  Mouse lung oedema caused by a toxic substance of Escherichia coli strains.

Authors:  I Kétyi; L Emödy; T Kontrohr; A Vertényi; S Pácsa; T A Avdeeva; N V Safonova; N K Golutova
Journal:  Acta Microbiol Acad Sci Hung       Date:  1978
View more
  30 in total

1.  Python erythrocytes are resistant to α-hemolysin from Escherichia coli.

Authors:  Casper K Larsen; Marianne Skals; Tobias Wang; Muhammad U Cheema; Jens Leipziger; Helle A Praetorius
Journal:  J Membr Biol       Date:  2011-11-08       Impact factor: 1.843

Review 2.  The different hemolysins of Escherichia coli.

Authors:  L Beutin
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

Review 3.  Escherichia coli in extra-intestinal infections.

Authors:  I Orskov; F Orskov
Journal:  J Hyg (Lond)       Date:  1985-12

4.  Role of cell-bound hemolysin as a pathogenicity factor for Serratia infections.

Authors:  W König; Y Faltin; J Scheffer; H Schöffler; V Braun
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

5.  In vivo effects of intravascularly applied Escherichia coli hemolysin: dissociation between induction of granulocytopenia and lethality in monkeys.

Authors:  D Vagts; H P Dienes; P J Barth; H Ronneberger; K D Hungerer; S Bhakdi
Journal:  Med Microbiol Immunol       Date:  1993-03       Impact factor: 3.402

Review 6.  The RTX pore-forming toxin α-hemolysin of uropathogenic Escherichia coli: progress and perspectives.

Authors:  Travis J Wiles; Matthew A Mulvey
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

7.  In vitro cytotoxic effect of alpha-hemolytic Escherichia coli on human blood granulocytes.

Authors:  O V Gadeberg; I Orskov
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

8.  A conserved PapB family member, TosR, regulates expression of the uropathogenic Escherichia coli RTX nonfimbrial adhesin TosA while conserved LuxR family members TosE and TosF suppress motility.

Authors:  Michael D Engstrom; Christopher J Alteri; Harry L T Mobley
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

9.  Hemolytic activity and invasiveness in strains of Proteus penneri.

Authors:  A Rozalski; K Kotełko
Journal:  J Clin Microbiol       Date:  1987-06       Impact factor: 5.948

10.  Superoxide generation by human neutrophils induced by low doses of Escherichia coli hemolysin.

Authors:  S Bhakdi; E Martin
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.